Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis
Authors' conclusion
Improvement in insulin sensitivity was proportional to weight and fat loss, with greater strength of association with tirzepatide. In regression analysis, tirzepatide was associated with greater improvement in insulin sensitivity per unit weight loss than semaglutide. The greater improvement in insulin sensitivity following treatment with tirzepatide was not simply attributable to greater weight or fat loss.
Study context
- Population
- People with T2D treated with metformin
- Comparison
- Tirzepatide 15 mg vs semaglutide 1 mg
- Primary endpoint
- Relationship between change in body weight and change in insulin sensitivity (clamp M value; Matsuda index)
- Follow-up
- 28 weeks
Methodological detailspost hoc, exploratory, double-blind, 28-week
- Post hoc
- Exploratory
- Double-blind
- 28-week
Primary result
As reported in the abstract
| Group | R with % weight change | p |
|---|---|---|
| Tirzepatide | −0.656 | p < 0.0001 |
| Semaglutide | −0.268 | p = 0.0820 |
R with % weight change
Tirzepatide−0.656
Semaglutide−0.268
p
Tirzepatidep < 0.0001
Semaglutidep = 0.0820
- Tirzepatide vs Semaglutide: P < 0.001 — greater improvement in clamp insulin sensitivity with tirzepatide
- Semaglutide vs Tirzepatide: P = 0.0242 vs. tirzepatide — less strong correlation with semaglutide
- Semaglutide vs Tirzepatide: P = 0.0461 — slope statistically different
Further findings
Matsuda index and change in fat mass analyses
- Relationships also assessed using Matsuda index and change in fat mass
Original publication
Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis. Diabetes Obes Metab. Published 6 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →